StreetInsider.com News Articles

Niagen Bioscience lists Tru Niagen supplement on Walmart.com

Thu, 06 Aug 2026 08:34:27 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its Tru Niagen NAD+ supplement is now available for purchase on Walmart.com, according to a company press release.

The initial product listing includes Tru Niagen 300 mg in 30-count and 90-count bottles. The company said it plans to expand the full range of Tru Niagen products on the platform over the following weeks.

"Expanding Tru Niagen's availability on Walmart.com makes our science-backed NAD+ solution more accessible to consumers nationwide," said Rob Fried, CEO of Niagen Bioscience. "It is another step in meeting consumers where they shop."

The company describes Tru Niagen as clinically shown to increase

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com.

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Thu, 06 Aug 2026 08:34:00 -0400

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States

The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed

Niagen Bioscience, Inc. (NAGE) Misses Q2 EPS by 1c

Tue, 04 Aug 2026 17:31:18 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) reported Q2 EPS of $0.01, $0.01 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $29.8 million versus the consensus estimate of $32.18 million.

For earnings history and earnings-related data on Niagen Bioscience, Inc. (NAGE) click here.

Form 10-Q Niagen Bioscience, Inc. For: Jun 30

Tue, 04 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26866017.html

Form 10-Q Niagen Bioscience, Inc. For: Jun 30

Tue, 04 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26866017.html

Form 8-K Niagen Bioscience, Inc. For: Aug 04

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865969.html

Form 8-K Niagen Bioscience, Inc. For: Aug 04

Tue, 04 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260804/26865969.html

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:02:00 -0400

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July

Launched Niagen Plus telehealth platform

Net sales of $29.8 million, including $24.2 million from Tru Niagen

Generated $1.6 million of operating cash flow year-to-date

Net income of $1.0 million and adjusted EBITDA of $3.0 million

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

Second Quarter 2026 Financial and Business Highlights

Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23%